SHS leads series-B round for Miracor

Participating parties in the round include existing investors Earlybird and Delta Partners. The Austrian government promotional bank aws Austria Wirtschaftservice has supported the transaction with an additional financing guarantee.

The investor believes that there is a great clinical demand for Miracor's technology. SHS was attracted by the growth potential of the firm as well as the company's approach to offering improved therapy for heart attack patients.

Company
Miracor Medical Systems was founded in 2008 and has developed the Miracor PICSO technology which can reduce myocardial injuries and revitalise the ischemic heart muscle. The Vienna-based company is planning to begin its "Prepare RAMSES" study along with initial sales to selected hospitals in Europe in 2011. A trial is expected to take place in 2012. Miracor currently employs eight people.

People
Hubertus Leonhardt is partner at SHS Gesellschaft für Beteiligungsmanagement.

Advisers
Equity – Weitnauer Rechtsanwälte (Legal).
Company – Herbst Vavrovsky Kinsky Rechtsanwälte (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Austria